23:06 , Jun 7, 2018 |  BC Extra  |  Company News

Management tracks: Alder, BIO

Neurology company Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) hired Robert Azelby as president and CEO, effective June 13. Azelby was EVP and chief commercial officer at Juno Therapeutics Inc., which Celgene Corp. (NASDAQ:CELG) acquired. The Biotechnology Innovation Organization...
19:05 , May 18, 2018 |  BC Week In Review  |  Company News

Atara, Memorial Sloan Kettering expand CAR-T deal

Atara Biotherapeutics Inc. (NASDAQ:ATRA) and Memorial Sloan Kettering Cancer Center (New York, N.Y.) expanded a 2014 deal in order to give Atara access to several MSKCC technologies including a CAR T construct and methods for...
22:28 , May 7, 2018 |  BC Extra  |  Company News

Management tracks: Adverum, Evolus

Adverum Biotechnologies Inc. (NASDAQ:ADVM) said President and CEO Amber Salzman has stepped down. CFO and SVP Leone Patterson is acting as interim president and CEO while the gene therapy company searches for a successor. Additionally,...
23:09 , Apr 6, 2018 |  BioCentury  |  Finance

Fundamentally driven

Continued struggles by the mega-cap bellwethers and the resurgence of volatility in global equity markets were the major themes of 1Q18, whipsawing biotech stocks throughout the quarter but leaving index values little changed on the...
18:24 , Mar 9, 2018 |  BC Week In Review  |  Financial News

Atara raises $150M in follow-on

Atara Biotherapeutics Inc. (NASDAQ:ATRA) raised $150 million on Feb. 28 through the sale of 4.3 million shares at $35 in a follow-on underwritten by J.P. Morgan, Cowen, Canaccord Genuity and Mizuho. The price is an...
16:18 , Mar 1, 2018 |  BC Extra  |  Financial News

Atara raises another $150M in latest follow-on

Atara Biotherapeutics Inc. (NASDAQ:ATRA) raised $150 million through the sale of 4.3 million shares at $35 in a follow-on underwritten by J.P. Morgan, Cowen, Canaccord Genuity and Mizuho. The price is an 18% discount to...
23:28 , Feb 26, 2018 |  BC Extra  |  Company News

Management tracks: Vertex, Basilea

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said CMO and EVP of Global Medicines Development and Medical Affairs Jeffrey Chodakewitz will retire, effective April 1. He is succeeded by Vertex SVP of Clinical Development and Medical Affairs Reshma...
22:33 , Feb 15, 2018 |  BC Extra  |  Company News

Management tracks: bluebird, Sangamo

Gene therapy company bluebird bio Inc. (NASDAQ:BLUE) promoted Alison Finger to chief commercial officer from SVP of marketing and product launch. Gene editing company Sangamo Therapeutics Inc. (NASDAQ:SGMO) hired Heather Turner as SVP and general counsel....
08:22 , Jan 26, 2018 |  BC Week In Review  |  Clinical News

Atara reports expanded access protocol data of tabelecleucel

Atara Biotherapeutics Inc. (NASDAQ:ATRA) reported data from a U.S. expanded access protocol study showing that IV tabelecleucel led to an objective response rate (ORR) of 83% among six patients with Rituxan rituximab-refractory Epstein-Barr virus (EBV)...
03:11 , Jan 13, 2018 |  BioCentury  |  Finance

JPM jolt

Fifteen biotechs that presented at the 2018 J.P. Morgan Healthcare Conference posted gains of at least 15%, with Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) leading the risers after announcing that its board rejected two unsolicited acquisition proposals...